And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is jammed with activities, starting with a celebration of ancient rituals, tidying up the Pharmalot campus and catching up on sundry chores. And what about you? This is a splendid time of year to enjoy the great outdoors. You could kill time by scavenging at yard sales. Or party like it’s 1999. Whatever you do, have a grand time. But be safe. See you soon …
Valeant Pharmaceuticals is finalizing a contract to hire Joe Papa, who currently runs Perrigo, as its next chief executive, the Wall Street Journal reports. The Perrigo board, however, must allow Papa to violate a noncompete clause in his contract. Valeant is seeking a replacement for Michael Pearson, who has presided over a stunning reversal of fortunes for the beleaguered drug maker.
AstraZeneca hopes to compile genome sequences and health records from up to 2 million people over the next decade, Nature writes. The drug maker is teaming with the Wellcome Trust Sanger Center and Human Longevity, which was founded by Craig Venter, and plans to use data from 500,000 participants in its own clinical trials, as well as medical samples gathered over the past 15 years. AstraZeneca is also collaborating with the Institute for Molecular Medicine, Finland as part of the deal.
About the Author Reprints
